|1.||Fallon, J T: 1 article (05/2003)|
|2.||Damico, L A: 1 article (05/2003)|
|3.||Wohlgensinger, C: 1 article (05/2003)|
|4.||Nemerson, Y: 1 article (05/2003)|
|5.||Himber, J: 1 article (05/2003)|
|6.||Roux, S: 1 article (05/2003)|
|7.||Riederer, M A: 1 article (05/2003)|
|8.||Kirchhofer, D: 1 article (05/2003)|
|1.||Venous Thrombosis (Deep-Vein Thrombosis)
04/01/1999 - "One hundred and five patients with acute proximal deep-vein thrombosis were randomized to receive a continuous intravenous infusion of napsagatran, a novel synthetic thrombin inhibitor, at a fixed dose of 5 mg/h (n = 36) or 9 mg/h (n = 25) for five days, or APTT-adjusted unfractionated heparin (UFH, n = 44) for the same time. "
09/01/1997 - "One hundred and ten patients with acute proximal deep-vein thrombosis were randomized in a sequential dose-finding design, to receive continuous intravenous infusion of napsagatran, a novel synthetic thrombin-inhibitor, at a fixed dose of 5 mg/h (n = 37) or 9 mg/h (n = 26), or APTT-adjusted unfractionated heparin (n = 47). "
09/01/1997 - "An exploratory trial of two dosages of a novel synthetic thrombin inhibitor (napsagatran, Ro 46-6240) compared with unfractionated heparin for treatment of proximal deep-vein thrombosis -- results of the European multicenter ADVENT trial."
04/01/1999 - "Differential inhibition of thrombin activity and thrombin generation by a synthetic direct thrombin inhibitor (napsagatran, Ro 46-6240) and unfractionated heparin in patients with deep vein thrombosis. "
09/01/1994 - "In contrast, both thrombus height and thrombus area were reduced (60% to 90%) by Ro 46-6240 in the 30-minute perfusion groups at all wall shear rates. "
09/01/1994 - "In the 5-minute experiments, thrombus height was reduced by Ro 46-6240 at shear rates of 100/s (85%) and 650/s (35%) but not at a shear rate of 2600/s, whereas thrombus area was not affected at any shear rate. "
05/01/2003 - "The antithrombotic effect obtained with the anti-TF antibody was comparable to the effect observed with the thrombin inhibitor napsagatran suggesting that in this animal model the thrombus propagation is highly TF dependent. "
04/01/1996 - "Neither heparin nor napsagatran decreased the thrombus volume after a 5-min perfusion. "
04/01/1996 - "High-dose heparin (70 U/kg/h) or napsagatran (10 microgram/kg/min) decreased the platelet-rich thrombus after a 20-min chamber perfusion. "
|1.||Ro 46-6240 (napsagatran)